| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | - | 8.981 | 15.527 | 21.711 | 40.561 | 83.371 |
| Total Income - EUR | - | - | - | - | - | 8.981 | 15.527 | 21.711 | 40.561 | 83.371 |
| Total Expenses - EUR | - | - | - | - | - | 533 | 3.371 | 2.670 | 13.752 | 23.960 |
| Gross Profit/Loss - EUR | - | - | - | - | - | 8.447 | 12.156 | 19.041 | 26.809 | 59.411 |
| Net Profit/Loss - EUR | - | - | - | - | - | 8.197 | 11.699 | 18.617 | 26.424 | 57.285 |
| Employees | - | - | - | - | - | 0 | 0 | 1 | 1 | 1 |
Check the financial reports for the company - Salderma Medical S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | - | 0 | 0 | 0 | 28.634 | 22.683 |
| Current Assets | - | - | - | - | - | 8.307 | 11.869 | 18.732 | 42.090 | 70.825 |
| Inventories | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Receivables | - | - | - | - | - | 310 | 505 | 13.198 | 17.612 | 40.709 |
| Cash | - | - | - | - | - | 7.997 | 11.364 | 5.534 | 24.478 | 30.116 |
| Shareholders Funds | - | - | - | - | - | 8.238 | 11.748 | 18.666 | 26.472 | 57.333 |
| Social Capital | - | - | - | - | - | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | - | - | - | 69 | 121 | 66 | 44.693 | 36.906 |
| Income in Advance | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Salderma Medical S.r.l.